Severity
Moderate
FDA Drug recall · Reported June 24, 2026
Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg.
Ajanta Pharma USA Inc recalled Aripiprazole Tablets USP, Rx only, 30 mg, 30 tablets, Marketed by: Ajanta Pharma USA Inc.… - a moderate-severity action.
Aripiprazole Tablets USP, Rx only, 30 mg, 30 tablets, Marketed by: Ajanta Pharma USA Inc.… was recalled by Ajanta Pharma USA Inc in June 24, 2026. Reason: Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole …. Check the official notice for the remedy. Verify recall #D-0594-2026 with the FDA Drug before acting.
The recall
Ajanta Pharma USA Inc issued this moderate-severity FDA Drug recall-Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole ….
Sourced from official FDA Drug enforcement records. Verify recall #D-0594-2026 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0594-2026) was formally reported on June 24, 2026, with the manufacturer initiating the action on May 27, 2026. It is classified under Moderate severity (Class II), with a current status of Ongoing. Ajanta Pharma USA Inc is listed as the recalling firm, operating out of Bridgewater, NJ. Federal records list the affected scope as 6,143 bottles.
The documented reason for this recall is: Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg. Distribution data in the federal record shows the product reached: U.S. Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 3,772 children & baby products recalls on record
Of 88,001 recalls with an agency hazard classification, 19,020 are high severity, 64,468 moderate, and 4,513 low. A further 16,157 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
6,143 bottles
Related Recalls
6
0 from same agency
Aripiprazole Tablets USP, Rx only, 30 mg, 30 tablets, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807, Made in India, NDC 27241-056-03.
Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Ongoing |
| Recall number | D-0594-2026 |
| Date reported | June 24, 2026 |
| Date initiated | May 27, 2026 |
| Recalling firm | Ajanta Pharma USA Inc |
| Firm location | Bridgewater, NJ |
| Affected scope | 6,143 bottles |
| Distribution | U.S. Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Two federal-filing-derived peer sets for this notice, both outside the same recalling firm and filing state so the neighborhoods are not firm or geographic containment.
Same archive severity grade (Moderate), closest by report date among other firms and states.
Same product category, closest by report date among other firms and states (deduped against the severity set).
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Showing 5 of 4006 other recalls in this category.
EEMB USA, doing business as A2batt, Inc., of Redlands, California · 2026-08-06
Shenzhen Okabesini Technology Co., Ltd., dba Okabesini-us, of China · 2026-08-06
· 2026-08-06
Changsha Yuelu District Ruiwu E-Commerce Co., Ltd., dba WURUI.BABY, of China · 2026-08-06
· 2026-07-30
Compare this recall with A2batt Recalls EEMB Lithium Coin Battery Chargers Due to Ri… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported June 24, 2026. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.